Urgent requirement for Business Analyst with MDM Informatica Exp @ Dallas, TX

[Dinesh kumar]

Hi there,

Please share resumes for the below position at the earliest possible.

Business Analyst - MDM Informatica

Dallas, TX

6 months contract

Start date: Immediate

Job Description:

We are looking for self-motivated " MDM Business Analyst with excellent communication and customer service skills. • 5+ years of experience working as a Business Analyst for MDM implementations. • Experience in Informatica MDM • General understanding of data quality concepts. Job Skills: • Experience in doing business analysis for Enterprise software implementations a must • Deep understanding of MDM object model, data model, hierarchies, trust/survivorship framework, data acquisition, CRM Systems understanding and functional services. Minimum Experience: 5 Yrs Roles & Responsibilities: • Experience to work with the subject matter experts to gather and document business requirements for MDM Implementations • Excellent verbal and written communication skills are essential • Excellent analytical skills. Education: Bachelor's Degree

Thanks in advance!!!

Regards,

Dinesh Kumar

Email: dine...@sightpectrum.com

Contact number: 201-203-2570

[research updates]

            4-fluoroisobutyrfentanyl powder (also known as 4-FIBF and p-FIBF) is an opioida is an analog of butyrfentanyl and structural isomer of 4-Fluorobutyrfentanyl and has been sold online as a designer drug. It is closely related to 4-fluorofentanyl, which has an EC50 value of 4.2 nM for the human ?-opioid receptor.

DESCRIPTION
Names: 4-Fluoroisobutyrfentanyl para-fluoroisobutyrfentanyl, N-(4-fluorophenyl)-N-(1-phenethylpiperidin 4-yl)isobutyramide pFIBF, 4-FIBF,

IUPAC name: N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide

Substance group: Other substances

This substance is included in Schedule I of the 1961 Single Convention on Narcotic Drugs

InChI
InChI=1S/C23H29FN2O/c1-18(2)23(27)26(21-10-8-20(24)9-11-21)22-13-16-25(17-14-22)15-12-19-6-4-3-5-7-19/h3-11,18,22H,12-17H2,1-2H3

InChI Key: OZDOSQNUJIXEOR-UHFFFAOYSA-N SMILES: O=C(C(C)C)N(C1=CC=C(F)C=C1)C2CCN(CCC3=CC=CC=C3)CC2

Formula: C23H29FN2O

Molar mass: 368.50 g·mol?1

Side effects
Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.

Legality
4-Fluoroisobutyrylfentanyl is a Schedule I controlled substance in the United States. In the UK, it is a Class A drug. In Canada, it is a Schedule I drug.

See also
3-Methylbutyrfentanyl
3-Methylfentanyl
4-Fluorofentanyl
?-Methylfentanyl
Acetylfentanyl
Acrylfentanyl
Furanylfentanyl
List of fentanyl analogues
Fentanyl analogues, in which the N-[1-(2-phenethyl)-4-piperidyl]aniline nucleus has additional radicals, either alone or in combination, attached as follows:

(a) an acetyl, propionyl, butenoyl or butanoyl radical, attached to the aniline nitrogen atom:

(b) 1 or more alkyl radicals, with up to 10 carbon atoms in total, attached to the ethyl moiety:

(c) any combination of up to 5 alkyl radicals and/or alkoxy radicals (each with up to 6 carbon atoms, including cyclic radicals) and/or halogen radicals, attached to each of the benzene rings

fentanyl-related substances includes any substance not otherwise controlled in any schedule…that is structurally related to fentanyl by one or more of the following modifications:

Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;
substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups;
substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;
replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; and/or
replacement of the N-propionyl group by another acyl group.

https://alpharesearchlab.net/product/buy-4-fluoroisobutyrfentanyl-powder/

https://alpharesearchlab.net/product/buy-4-fluoroisobutyrfentanyl-powder/

Buy UR-144 Powder
Buy UR-144 Powder (TMCP-018, KM-X1, MN-001, YX-17) is a drug invented by Abbott Laboratories, that acts as a selective full agonist of the peripheral cannabinoid receptor CB2, but with much lower affinity for the psychoactive CB1 receptor.

Pharmacology
UR-144 has high affinity for the CB2 receptor with a Ki of 1.8 nM but 83x lower affinity for the CB1 receptor with a Ki of 150 nM. It was found to possess an EC50 of 421 nM for human CB1 receptors, and 72 nM for human CB2 receptors. UR-144 produces bradycardia and hypothermia in rats at a dose of 10 mg/kg, suggesting weak cannabinoid-like activity.

Chemically it is closely related to other 2,2,3,3-tetramethylcyclopropyl synthetic cannabinoids like A-796,260 and A-834,735 but with a different substitution on the 1-position of the indole core, in these compounds its 1-pentyl group is replaced with alkylheterocycles like 1-(2-morpholinoethyl) and 1-(tetrahydropyran-4-ylmethyl).

Chemical and physical data
Formula: C21H29NO

Molar mass: 311.461 g/mol g·mol?1

Dose
Inhalation (tentative due to a lack of information)

Range: 2.5 to 20 mg
Most people have been exposed to the drug in the form of “blends” that contain varying levels of UR-144. It’s not wise to use those products.

Timeline
Inhalation (tentative due to a lack of information)
Total: 1 – 2 hours
Onset: Under 10 minutes
See also
AB-001
AM-1221
4-HTMPIPO
FAB-144
JTE 7-31
JWH-018
N-(S)-Fenchyl-1-(2-morpholinoethyl)-7-methoxyindole-3-carboxamide
XLR-11
Tetramethylcyclopropylfentanyl

https://alpharesearchlab.net/product/buy-ur-144-powder-online/

https://alpharesearchlab.net/product/buy-ur-144-powder-online/



Buy THJ-2201 crystal
Buy THJ-2201 crystal an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.

It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.

Summary sheet: THJ-2201
THJ-2201 (1-?[(5-?fluoropentyl)-?1H-?indazol-?3-?yl](naphthalen-?1-?yl)methanone) is a synthetic cannabinoid and analog of AM-2201. It has been marketed by many research chemical vendors as a legal alternative to the popular AM-2201, which had been banned in 2011.

Cannabinoids are commonly smoked or vaporized to achieve a quick onset of effects and rapid offset. THJ-2201 is orally active when dissolved in a lipid, which can increase the duration significantly. Like other cannabinoids, it is insoluble in water but dissolves in ethanol and lipids.

Unlike cannabis, the chronic abuse of synthetic cannabinoids has been associated with multiple deaths and more dangerous side effects and toxicity in general. Therefore, it is strongly discouraged to take this substance for extended periods of time or in excessive doses.

Pharmacology
Although this substance has not been formally studied, from analysis of the structure, it is presumed that THJ-2201 has a similar binding profile to that of AM-2201 and matches many of the in vivo properties of ?9-THC. As with AM-2201, this compound is believed to act as a potent full agonist to the central CB1 and peripheral CB2 receptors with Ki values of 1.0 and 2.6nM respectively. However, the role of these interactions and how they result in the cannabinoid high experience continues to remain elusive.

Subjective effects
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.

Chemical and physical data
Formula C23H21FN2O
Molar mass 360.42 g/mol g·mol?1
3D model (JSmol) Interactive

See also
AM-694
AM-1235
AM-2232
AM-2233
FUBIMINA
JWH-018
List of AM cannabinoids
List of JWH cannabinoids
NM-2201
THJ-018

https://alpharesearchlab.net/product/buy-thj-2201-crystal/

https://alpharesearchlab.net/product/buy-thj-2201-crystal/



BUY SDB-006 POWDER
BUY SDB-006 POWDER SDB-006 is a drug that acts as a potent agonist for the cannabinoid receptors, with an EC50 of 19 nM for human CB2 receptors, and 134 nM for human CB1 receptors. It was discovered during research into the related compound SDB-001 which had been sold illicitly as “2NE1”. SDB-006 metabolism has been described in literature.

Synthetic cannabinoids are the largest and most structurally diverse class of new psychoactive substances, with manufacturers often using isomerism to evade detection and circumvent legal restriction. The regioisomeric methoxy? and fluorine?substituted analogs of SDB?006 (N?benzyl?1?pentyl?1H?indole?3?carboxamide) were synthesized and could not be differentiated by gas chromatography–mass spectrometry (GC–MS), but were distinguishable by liquid chromatography–quadrupole time?of?flight–MS (LC–QTOF–MS). In a fluorescence?based plate reader membrane potential assay, SDB?006 acted as a potent agonist at human cannabinoid receptors (CB1 EC50 = 19 nM). All methoxy? and fluorine?substituted analogs showed reduced potency compared to SDB?006, although the 2?fluorinated analog (EC50 = 166 nM) was comparable to known synthetic cannabinoid RCS?4 (EC50 = 146 nM). Using biotelemetry in rats, SDB?006 and RCS?4 evoked comparable reduction in body temperature (~0.7°C at a dose of 10 mg/kg), suggesting lower potency than the recent synthetic cannabinoid AB?CHMINACA (>2°C, 3 mg/kg).

Technical Information
Formal Name: 1-pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide
CAS Number: 695213-59-3
Molecular Formula: https://alpharesearchlab.net/product/buy-sdb-006-powder/C21H24N2O
Formula Weight: 320.4
Purity: ?98%
Formulation: A crystalline solid
?max: 218, 291 nm
SMILES: CCCCCN1C=C(C(NCC2=CC=CC=C2)=O)C3=C1C=CC=C3
InChi CodeInChI=1S/C21H24N2O/c1-2-3-9-14-23-16-19(18-12-7-8-13-20(18)23)21(24)22-15-17-10-5-4-6-11-17/h4-8,10-13,16H,2-3,9,14-15H2,1H3,(H,22,24)
InChi Key: OLACYTSBFXCDOH-UHFFFAOYSA-N
Shipping & Storage Information
Storage: -20°C
Shipping: Room Temperature in continental US; may vary elsewhere
Stability: ? 2 years
WARNING This product is not for human or veterinary use.

See also
5F-CUMYL-PINACA
5F-SDB-006
APINACA
CUMYL-PICA
CUMYL-PINACA
CUMYL-THPINACA
SDB-001
SDB-005
STS-135

https://alpharesearchlab.net/product/buy-sdb-006-powder/

https://alpharesearchlab.net/product/buy-sdb-006-powder/

[research updates]

[research updates]

Buy 5-MeO-MIPT Powder
Buy 5-MeO-MIPT Powder (known by the street name Moxy or Moxie) is a psychedelic and hallucinogenic drug, used by some as an entheogen. It has structural and pharmacodynamic properties similar to the drugs 5-MeO-DiPT, DiPT, and MiPT. It is commonly used as a “substitute” for 5-MeO-DiPT because of the very similar structure and effects. This certified solution standard is suitable for Moxy testing methods by GC/MS or LC/MS testing applications in clinical toxicology, urine drug testing, or forensic analysis. The use of 5-MeO-MiPT has recently been reported in Europe.

Chemistry
5-MeO-MiPT is in a class of compounds commonly known as tryptamines, and is the N-methyl-N-isopropyl homologue of the psychedelic, 5-MeO-DMT. The full name of the chemical is 5-methoxy-N-methyl-N-isopropyltryptamine.

5-MeO-MiPT causes the ehrlich reagent to turn purple then fade to faint blue. It causes the marquis reagent to go yellow through to black.

Dosage
Orally, 5-MeO-MiPT is active at 4-6 mg. The drug can also be smoked, but unlike most other tryptamines, this route requires a much higher dosage. 10–20 mg is usually smoked. It typically produces a very strong odor.

Some users report activity as low as 1 mg while others report no activity up to 20 mg, this compound seems to be highly sensitive to the individual and any potential researchers should keep this in mind. Titrating the dose would be especially important with this compound.

Some users report little to no visual activity until doses of 10 mg or higher are taken. This chemical proves very useful for opening up and expressing oneself much like MDMA (3,4-methylenedioxymethamphetamine) and may be a useful chemical in psychedelic therapy.

Pharmacology
The mechanism that produces the hallucinogenic and entheogenic effects of 5-MeO-MiPT is thought to result primarily from 5-HT2A receptor agonism, although additional mechanisms of action such as inhibition of MAO may be involved also. 5-MeO-MiPT binds most strongly to 5-HT1A receptors; it also shows fairly strong binding affinity to the SERT and NET, thereby acting as a moderately potent serotonin-norepinephrine reuptake inhibitor. These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.

Chemical and physical data
Formula: C15H22N2O

Molar mass: 246.35 g/mol g·mol?1

See also
MIPT
5-MeO-DMT
5-MeO-DiPT

http://alpharesearchlab.net/product/buy-5-meo-mipt-powder/

http://alpharesearchlab.net/product/buy-5-meo-mipt-powder/

• Opens in a new window